PYXS vs. ALDX, OMER, TSVT, GTHX, FHTX, DSGN, QURE, PBYI, IMMP, and AKBA
Should you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Aldeyra Therapeutics (ALDX), Omeros (OMER), 2seventy bio (TSVT), G1 Therapeutics (GTHX), Foghorn Therapeutics (FHTX), Design Therapeutics (DSGN), uniQure (QURE), Puma Biotechnology (PBYI), Immutep (IMMP), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability.
Pyxis Oncology has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
Aldeyra Therapeutics' return on equity of -24.69% beat Pyxis Oncology's return on equity.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 8.4% of Pyxis Oncology shares are held by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Aldeyra Therapeutics received 460 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 69.36% of users gave Aldeyra Therapeutics an outperform vote.
Pyxis Oncology currently has a consensus target price of $8.80, indicating a potential upside of 112.05%. Aldeyra Therapeutics has a consensus target price of $9.33, indicating a potential upside of 136.29%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Pyxis Oncology.
In the previous week, Pyxis Oncology had 13 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 14 mentions for Pyxis Oncology and 1 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.85 beat Pyxis Oncology's score of 0.56 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.
Summary
Aldeyra Therapeutics beats Pyxis Oncology on 9 of the 13 factors compared between the two stocks.
Get Pyxis Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pyxis Oncology Competitors List
Related Companies and Tools
